We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App




Immunoassay Systems Compared for Trisomy Screenings

By LabMedica International staff writers
Posted on 25 Jul 2017
The biochemical serum markers free β-human chorionic gonadotropin (hCGβ) and pregnancy associated plasma protein A (PAPP-A) are used in screening for trisomy 21 (T21), trisomy 18 (T18), and trisomy 13 (T13) during the first trimester.

The biochemical analysis of hCGβ and PAPP-A can be performed on different analytical systems and it is important not only to know the analytical variation but also the screen positive rate and the detection rate for these different systems.

Clinical biochemists at the Copenhagen University Hospital Hvidovre (Denmark) collected serum samples from 944 singleton pregnant women attending for first trimester during a two-month period between April 2014 and June 2014. More...
The median maternal age was 31 years (range 17–47 years) and the median gestational age was 11+2 (range 8+1 − 14+0 weeks of gestation) at time of sampling. Serum samples from 70 women carrying a fetus affected by T21 (n=50), T18 (n=14) or T13 (n=6) were compared.

Blood samples were collected into tubes with clot activator and gel separator. The hCGβ and PAPP-A concentrations were routinely analyzed on Kryptor fully automated immunoanalyzer at the time of testing. After storage at −80 °C, the samples were re-analyzed on Cobas 6000 in the autumn of 2015. The measurement principle of Kryptor is time-resolved amplified cryptate emission technology while the Cobas employs electro-chemiluminescence immunoassay. The karyotype was determined with either amniocentesis or chorionic villus sampling or by karyotyping after birth. All measurements of hCGβ and PAPP-A were transformed to multiples of the median (MoM) values for each analytical platform.

The scientists found that hCGβ MoM and PAPP-A MoM results from Kryptor correlated well with those from Cobas. However for the screening population, the hCGβ and PAPP-A results in MoM from Kryptor and Cobas were significantly lower on Cobas when compared to Kryptor. The number of pregnant women with a risk above 1:300 for T21 was 48 for both Cobas and Kryptor, although a few patients only had a high risk with one of the methods. Overall, the screen positive rate was 5.1% for both instruments. In the trisomy groups the calculated risks for T21, T18, and T13 agreed well between Cobas and Kryptor.

The authors concluded that although, in the screening population, hCGβ and PAPP-A measurements performed on Cobas were significantly lower than on Kryptor, but the same screen positive rate of 5.1% was found. The two analytical instruments performed equally well in detecting pregnancies with T21, T18, or T13 karyotypes when hCGβ and PAPP-A were included in the risk calculation. The study was published on July 11, 2017, in the journal Practical Laboratory Medicine.

Related Links:
Copenhagen University Hospital Hvidovre


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.